Coronavirus Legislation On Pharma Supply Chain Aims to Repatriate Manufacturing
But bipartisan bill only mandates a study on how the US could restore domestic manufacturing, reduce dependence on China.
You may also be interested in...
Whether major drug shortages result from the COVID-19 pandemic or not, manufacturers would face greater reporting requirements, especially for APIs.
President dismisses fears of drug shortages as White House prepares to deliver US from dependence on China’s pharmaceutical manufacturing complex.
USP information suggests many firms in India, which is restricting exports of the antibiotic, as well as China, produce it for the US market.